Lactobacillus Brevis Nbrc 3345
Also known as: Lactobacillus brevis NBRC 3345, IFO 3345, Lactobacillus brevis, Levilactobacillus brevis NBRC 3345
Overview
Levilactobacillus brevis NBRC 3345, formerly known as Lactobacillus brevis NBRC 3345, is a specific strain of lactic acid bacteria (LAB) categorized as Gram-positive and heterofermentative. It is naturally found in fermented foods and the human gut. This strain is known for its ability to produce lactic acid, acetic acid, carbon dioxide, and ethanol via the phosphoketolase pathway. A notable characteristic of NBRC 3345 is its resilience, demonstrating survival under acidic conditions and moderately high temperatures, which suggests potential viability within the gastrointestinal tract. While *L. brevis* species are generally recognized for their probiotic potential and use in fermented products, specific clinical research on the NBRC 3345 strain is currently limited. Most available data are derived from genomic analyses and in vitro studies, with a scarcity of large-scale randomized controlled trials or meta-analyses to substantiate specific health benefits.
Benefits
Currently, there are no high-quality randomized controlled trials (RCTs) or systematic reviews specifically on *Levilactobacillus brevis* NBRC 3345 that meet strict criteria for establishing specific health benefits. Therefore, no quantified effect sizes or clinical significance can be reliably stated for this particular strain. While general *L. brevis* strains have been studied for their potential in gut microbiota modulation and antimicrobial activity through organic acid production, direct clinical evidence for NBRC 3345 is lacking. Although NBRC 3345 shares genetic features with other *L. brevis* strains that may confer resilience and probiotic potential, these are theoretical benefits based on genomic data rather than confirmed clinical outcomes. Without robust clinical trials, any claims regarding specific health benefits for NBRC 3345 remain unsubstantiated.
How it works
*Levilactobacillus brevis* NBRC 3345 primarily functions by fermenting sugars through the phosphoketolase pathway, yielding lactic acid, acetic acid, carbon dioxide, and ethanol. This metabolic activity creates an acidic environment that can be inhibitory to the growth of certain pathogens. Genomic analyses of NBRC 3345 have identified the presence of CRISPR-Cas systems, which are adaptive immunity mechanisms that protect the bacteria against phages and plasmids, potentially enhancing the strain's stability and survival. The strain's inherent tolerance to acidic conditions and moderate heat is believed to facilitate its survival as it transits through the gastrointestinal tract, allowing for potential transient colonization or interaction with the host's existing microbiome. Its molecular targets include various carbohydrate transporters and enzymes integral to its heterofermentative pathways.
Side effects
No specific safety data or adverse event reports directly attributable to *Levilactobacillus brevis* NBRC 3345 have been found in the scientific literature. Generally, *L. brevis* species are considered safe (GRAS - Generally Recognized As Safe) and are widely utilized in fermented foods and various probiotic formulations. There are no known contraindications or significant drug interactions reported for *L. brevis* strains as a whole. However, it is important to note that antibiotic resistance can be acquired by bacteria, including *L. brevis*, through mechanisms like conjugation. The potential for antibiotic resistance acquisition is strain-dependent, and further investigation specific to NBRC 3345 would be required to fully assess this risk. Overall, while the species is considered safe, specific safety data for this particular strain are limited.
Dosage
Due to the absence of clinical trials specifically evaluating *Levilactobacillus brevis* NBRC 3345, there are no established clinical dosing guidelines for this strain. Typical probiotic dosages for *Lactobacillus* species in general range from 10^8 to 10^10 Colony Forming Units (CFU) per day in supplement formulations. However, the effective dose for NBRC 3345 for any specific purpose remains undetermined. Given the strain's survival characteristics, which include tolerance to acidic conditions, any formulation containing NBRC 3345 should ideally be designed to protect the bacteria from gastric acid to ensure its successful delivery to the intestines, where it can potentially exert its effects.
FAQs
Is NBRC 3345 proven effective as a probiotic?
No, there is currently no high-quality clinical evidence, such as randomized controlled trials, to support specific health benefits or probiotic efficacy for *Levilactobacillus brevis* NBRC 3345.
Is it safe?
Based on general species-level data for *L. brevis*, it is likely safe and commonly used in foods. However, specific safety data and adverse event reports for the NBRC 3345 strain are limited.
How does it survive digestion?
*Levilactobacillus brevis* NBRC 3345 exhibits tolerance to acidic conditions and moderately high temperatures, which may aid its survival through the harsh environment of the stomach, allowing it to reach the intestines.
Research Sources
- https://pmc.ncbi.nlm.nih.gov/articles/PMC9204096/ – This genomic analysis of 83 *L. brevis* strains, including NBRC 3345, investigated CRISPR-Cas system diversity and evolutionary relationships. The study found that NBRC 3345 shares spacer patterns with closely related strains, suggesting a common ancestor. This research provides insights into the strain's genetic resilience but does not offer clinical data on health outcomes.
- https://en.wikipedia.org/wiki/Levilactobacillus_brevis – This source provides general information about *Levilactobacillus brevis*, including its classification, metabolic characteristics, and acid tolerance. It describes the foundational microbiological properties of the species, such as its heterofermentative metabolism and production of various organic acids, which contribute to its survival and potential interactions in different environments.
- https://www.ncbi.nlm.nih.gov/Taxonomy/Browser/wwwtax.cgi?mode=Info&id=1580&lvl=3&keep=1&srchmode=1&unlock&mod=1&log_op=modifier_toggle – This NCBI Taxonomy Browser entry provides detailed taxonomic information for *Levilactobacillus brevis*, including its classification within the bacterial kingdom. It confirms the scientific name and provides links to related genetic and biological data, serving as a foundational reference for the species' identity and characteristics.
- https://www.jcm.riken.jp/cgi-bin/jcm/jcm_keyword?AN=Lactobacillus&BN=brevis&CN=&DN= – This source from the Japan Collection of Microorganisms (JCM) provides information related to *Lactobacillus brevis* strains, likely including details about their isolation, characteristics, and availability for research. It serves as a reference for microbiological studies and strain identification within scientific collections.
Recommended Articles
Top Ingredients for Optimal Gut Health
Fiber, probiotics, prebiotics, hydration, and fermented foods are crucial for maintaining healthy digestion and gut function.
Best Probiotic Strains & CFU for Health
Certain probiotic strains like Lactobacillus and Bifidobacterium, with CFU counts ranging from 1 billion for general wellness to 100 billion for conditions like IBS, are most beneficial.
Best Probiotic Strains for Your Health Goals
Certain probiotic strains offer targeted benefits for digestive health, immune support, weight management, and mental health.
Top Digestive Health Ingredients
Dietary fiber, probiotics, and natural ingredients like ginger and peppermint oil are essential for improving digestive health.